Skip to Content
Søk Menu

ASH2020: The First-in-Class Anti-CD47 Antibody for AML

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Related

Increased Relative Risk of Cancer for Relatives to Patients with Myelodysplastic Neoplasms and Leukemia

/ Nikolaj Juul Nitschke / Kirsten Grønbæk
KreftLeukemi
Anand P. Jillella

Dramatic improvement in 1-year survival for patients with acute promyelocytic leukemia

/ Anand P. Jillella
ASH22Leukemi Play the Video 3:58

Late-Breaking from ASH22 – Zanubrutinib has Now Proven Superiority to Ibrutinib

/ BestPractice Nordic
ASH22CLLLeukemi
Martin F. Kaiser

Clinical results from the UK Optimum/Muknine Trial

/ Martin F. Kaiser
ASH21LeukemiMyelomatose Play the Video 6:04
Florence Ajchenbaum-Cymbalista

A new clinical presentation of chronic lymphocytic leukemia

/ Florence Ajchenbaum-Cymbalista
ASH21Leukemi Play the Video 2:39

Early vs Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma

/ Aurore Perrot
ASH20Myelomatose Play the Video 7:49

New Treatment Relapsed/Refractory Mantle Cell Lymphoma - data from phase 1 study

/ Maria Lia Palomba
ASH20Lymfom Play the Video 12:30

DARA to Rd continues to demonstrate a superior PFS benefit

/ Shaji K. Kumar
ASH20Myelomatose Play the Video 7:23

Promising clinical response for CD19-CART-cell therapy in CLL

/ Ohad Benjamini
ASH20KLL Play the Video 9:13
Back to top